Clinical Trials Sponsored by Durata Therapeutics, Inc.

Total 2991 results

Durata Therapeutics International BV (an Affiliate...

Withdrawn

Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis (AHOM)

Osteomyelitis
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis

Osteomyelitis

Ukraine
Durata Therapeutics Inc., an affiliate of Allergan...

Withdrawn

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

Community Acquired Pneumonia

United States
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Abscess | Cellulitis | Surgical Site Infection | Wound Infection

United States, Bulgaria, Estonia, Hungary, Israel, Korea, Republic of, Latvia, Lithuania, Romania, Russian Federation, Slovakia, South Africa, Taiwan, Ukraine
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

Bacterial Infections.

United States, Estonia
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Abscess | Cellulitis | Surgical Site Infection | Wound Infection

United States, Ukraine, Canada, Croatia, Georgia, Germany, Poland, Russian Federation
Durata Therapeutics Inc., an affiliate of Allergan...

Completed

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Abscess | Cellulitis | Surgical Site Infection | Wound Infection

United States, Bulgaria, Croatia, Estonia, Georgia, Hungary, Latvia, Romania, Russian Federation, Serbia, South Africa, Ukraine
Dermata Therapeutics

Active, not recruiting

DMT310-005 Topical in the Treatment of Acne Rosacea

Acne Rosacea

United States
Dermata Therapeutics

Completed

DMT310-001 Topical in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Dermata Therapeutics

Completed

DMT310-003 Topical in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Dermata Therapeutics

Completed

DMT210 Topical Gel in the Treatment of Atopic Dermatitis

Atopic Dermatitis

United States
Dermata Therapeutics

Recruiting

DMT310-009 Topical in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Dermata Therapeutics

Completed

DMT210 Topical Gel in the Treatment of Acne Rosacea

Acne Rosacea

United States
Medico's Hirata Inc.

Terminated

Safety and Efficacy of SYM-SV/DS-002 in Patients With Severe Aortic Stenosis

Severe Aortic Stenosis

Japan
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Tinea Pedis | Tinea Cruris

United States
Therapeutics, Inc.

Completed

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

Scalp Psoriasis

United States
Therapeutics, Inc.

Completed

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

Tinea Pedis

United States, Puerto Rico
Therapeutics, Inc.

Completed

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

Plaque Psoriasis

United States, Georgia, Ukraine
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

Plaque Psoriasis

United States
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With IgA Nephropathy (ALIGN)

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Spain, Canada, Taiwan, Hong Kong, China, New Zealand, United Kingdom, Korea, Republic of, Australia, Germany, France, India, Japan, Czechia, Argentina, Italy, Colombia, Ireland, Brazil, Poland, Portugal
Millendo Therapeutics US, Inc.

Terminated

Nevanimibe HCl for the Treatment of Classic CAH

Congenital Adrenal Hyperplasia

Spain, Israel, France, Brazil, Czechia
Cascadian Therapeutics Inc.
Celldex Therapeutics

Completed

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

Advanced Breast Carcinoma | Advanced Ovarian Carcinoma

United States
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

Diabetic Kidney Disease | Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | IgA Nephropathy | Diabetic Nephropathy Type 2 | Alport Syndrome

United States, Spain, Korea, Republic of, Australia, Italy, United Kingdom
Millendo Therapeutics US, Inc.

Terminated

A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

Cushing Syndrome

United States, United Kingdom
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
Chinook Therapeutics, Inc. (formerly Aduro)

Terminated

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer

United States
Viridian Therapeutics, Inc.

Not yet recruiting

A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Thyroid Eye Disease

United States
ImmuneOncia Therapeutics Inc.

Not yet recruiting

A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (TMB-H)

TMB-H | Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
Axsome Therapeutics, Inc.

Recruiting

Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol (PARADIGM)

Major Depressive Disorder

United States
Actym Therapeutics, Inc.

Not yet recruiting

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Solid Tumor

Australia
Nested Therapeutics, Inc

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

Australia
Viracta Therapeutics, Inc.

Recruiting

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Advanced Cancer

Spain
Biora Therapeutics, Inc.

Recruiting

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

Healthy

United States
Pliant Therapeutics, Inc.

Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor

United States
Iambic Therapeutics, Inc

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2 Mutation-Related Tumors

United States

Clinical Trials Sponsored by Durata Therapeutics, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations